Johnson & Johnson (JNJ) Q2 Earnings Preview: What to Watch
JNJ enters Q2 with a 25% YTD gain. We break down the revenue estimates, segment performance, and the critical questions for management.
The setup
Johnson & Johnson management raised full-year guidance following a strong Q1 2026 performance. The company now projects revenue between $100.3 billion and $101.3 billion, with adjusted EPS guidance set at $11.45 to $11.65.
CEO Joaquin Duato is prioritizing growth in Innovative Medicine and MedTech to offset the revenue decline from Stelara. Analysts remain focused on the company's ability to execute this transition while managing global macroeconomic pressures.
- Vamil Divan of Guggenheim maintains a Buy rating with a $270 price target.
- David Risinger of Leerink Partners upgraded the stock to Outperform with a $265 target.
- Matt Miksic of Barclays holds an Equal-Weight rating with a $255 target.
- Geopolitical tensions in the Middle East and Russia-Ukraine continue to impact global supply chain costs.
Consensus numbers
Market expectations for the second quarter are centered on consistent performance across core segments. Analysts are looking for evidence that new oncology and immunology assets are gaining sufficient traction to replace legacy revenue streams.
The company has a history of exceeding quarterly expectations, as shown in the data below.
- Q2 2026 EPS estimate: $2.85.
- Q2 2026 revenue estimate: $25.18 billion.
- Q1 2026 actual EPS: $2.46 (vs $2.46 estimate).
- Q4 2025 actual EPS: $2.80 (vs $2.76 estimate).
What we'll watch on the call
The earnings call will likely center on the durability of the Innovative Medicine segment. Investors need clarity on how the company is managing biosimilar competition for Stelara.
MedTech margins remain a point of contention due to shifting global tariff structures. Management's commentary on the DePuy Synthes orthopaedics separation will also be a key indicator of future capital allocation.
- Growth rates for Darzalex, Tremfya, and Carvykti.
- Commercialization progress for the ICOTYDE pipeline asset.
- Impact of U.S.-China trade relations on MedTech supply chain costs.
- Updates on interest income relative to the current interest rate environment.
Fintwit's AI verdict
The quantitative model suggests that the current valuation reflects a high degree of confidence in the company's pipeline execution. While macroeconomic headwinds persist, the historical trend of earnings surprises provides a tailwind for the upcoming print.
Investors should monitor the gap between current analyst targets and the price action immediately following the July 15 release.